You are here:

Archived: aprepitant (Emend)

Advice

following a full submission:

aprepitant (Emend) as part of combination therapy is not recommended for use within NHS Scotland for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

The aprepitant regimen showed a significant difference compared to the standard regimen in terms of the primary end-point of complete response for the acute phase only. No superiority for the aprepitant regimen could be demonstrated for the prevention of nausea.

The economic case for aprepitant in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy has not been demonstrated.

Drug Details

Drug Name: aprepitant (Emend)
SMC Drug ID: 242/06
Manufacturer: MSD
Indication: Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy
BNF Category:
Sub Category: 4.6 Drugs used in nausea and vertigo
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 March 2006

Current Advice

Resubmission 7 November 2011

Back